Malecare is proud to announce that we are now partnering with the Clinical Trials Resource Center. This partnership allows us to offer you, through our web site (www.malecare.org), CenterWatch’s data base of clinical trials that are being conducted both in the United States and internationally. CenterWatch is the leading publisher of information on clinical research [...]
Thinking out of the box, a new concept to fight cancer, including prostate cancer, has been developed. The strategy is simple, fight cancer with cancer! In a very small phase one trial researchers at the Rogosin Institute have taken encapsulated tumor cells from mice and made a bead from a seaweed-derived sugar called agarose. Then, [...]
We all know it, advanced prostate cancer not only affects the survivor, but it also affects his family. When diagnosed with advanced prostate cancer, the most common treatment is androgen deprivation therapy (ADT) which causes many side effects. These side effects include (but are not limited to) fatigue, nausea, hot flashes, pain, constipation and sexual [...]
One of our biggest disputes around hormone deprivation (ADT) concerns the question of scheduling. Traditionally, ADT involved staying on the therapy drug forever. However, ADT causes significant side effects that negatively impacts both the quality of life as well as posing potential significant medical problems. Over the last five or so years there has been [...]
Researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Walter Reed Army Medical Center evaluated metastasis-free survival (MFS) and overall survival (OS) among men with a biochemical reoccurrence (PSA only) of prostate cancer after having received a radical prostatectomy but did not receive additional therapy until developing metastases […]
A PSA only recurrence (biochemical failure) post a primary treatment for prostate cancer is relatively common, approximately 30% of those treated! A biochemical failure is characterized a return of increasing PSA without any other evidence of cancer on a scan. Failure can happen immediately after primary treatment has been completed or many years after the [...]
To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for men with prostate cancer, researchers from the University of Illinois at Chicago and the Hind T. Hatoum & Company, Chicago, IL. evaluated a large contingent of men who had been diagnosed with prostate cancer from January 2003 to October [...]
Researchers at the Department of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts performed an evaluation of the natural history of castration-resistant non-metastatic prostate cancer. For their analysis, the researchers used data from 331 subjects in a placebo group of a randomized controlled trial to evaluate the relations of disease and host characteristics with time [...]
This study estimated and projected the number of years of potential life lost (YPLL) among men who die of prostate cancer(advanced prostate cancer) in the United States from 2004 through 2050 and compare the projections by race/ethnicity and age, accounting for demographic changes and population growth. The researchers applied the life expectancy method to estimate [...]
What is the primary treatment for men with advanced prostate cancer? We all know the answer, it is hormone therapy. Almost without exception, when we get diagnosed, we are put on to hormone therapy (ADT). ADT makes us feel terribly, it affects our stamina, our memory, our attention span, gives us hot flashes and weakens [...]
